{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:56:41Z","timestamp":1775753801073,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Holland Top Sector Life Sciences & Health","award":["LSHM17074"],"award-info":[{"award-number":["LSHM17074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03788-9","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:45:31Z","timestamp":1773297931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5054-1569","authenticated-orcid":false,"given":"Mieke L. M.","family":"Bentvelzen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-4337","authenticated-orcid":false,"given":"Said","family":"el Bouhaddani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno N.","family":"Concepcion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-7718","authenticated-orcid":false,"given":"Harald E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7517-7348","authenticated-orcid":false,"given":"Shasti C.","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6379-1240","authenticated-orcid":false,"given":"Lydia G.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone A.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"TOFA-PREDICT author group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavish J.","family":"Bhansing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra T. A.","family":"van Bijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radjesh J.","family":"Bisoendial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenny","family":"van Bon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim L. T. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno W. R.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmerik F. A.","family":"Leijten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z. Nazira","family":"Jahangier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid M.","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siska","family":"Wijngaarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvana W.","family":"Kadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoaneta C.","family":"Comarniceanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-6486","authenticated-orcid":false,"given":"Simon C.","family":"Mastbergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2361-2803","authenticated-orcid":false,"given":"Paco M. J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"1","key":"3788_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primer. 2021;7(1):1\u201317.","journal-title":"Nat Rev Dis Primer"},{"issue":"1","key":"3788_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/2475530318812244","volume":"4","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. J Psoriasis Psoriatic Arthritis. 2019;4(1):31\u201358.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"3788_CR3","unstructured":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheumatic Dis. Available from: https:\/\/ard.bmj.com\/content\/79\/6\/700.1.abstract. Cited 2024 Oct 6."},{"issue":"5","key":"3788_CR4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"3788_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3899\/jrheum.190677","volume":"47","author":"M Zardin-Moraes","year":"2020","unstructured":"Zardin-Moraes M, da Silva ALFA, Saldanha C, Kohem CL, Coates LC, Henrique LR, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis. J Rheumatol. 2020;47(6):839\u201346.","journal-title":"J Rheumatol"},{"issue":"7","key":"3788_CR6","first-page":"687","volume":"52","author":"GH Koc","year":"2025","unstructured":"Koc GH, Kok MR, Snoeck Henkemans SVJ, Luime JJ, Tchetverikov I, van der Kaap JH, et al. The effect of early attainment of minimal disease activity on radiographic outcomes: a real-world longitudinal cohort study in psoriatic arthritis. J Rheumatol. 2025;52(7):687\u201392.","journal-title":"J Rheumatol"},{"issue":"2","key":"3788_CR7","doi-asserted-by":"publisher","first-page":"e002706","DOI":"10.1136\/rmdopen-2022-002706","volume":"8","author":"SVJ Snoeck Henkemans","year":"2022","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Kasiem FR, et al. Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis. RMD Open. 2022;8(2):e002706.","journal-title":"RMD Open"},{"issue":"2","key":"3788_CR8","doi-asserted-by":"publisher","first-page":"101693","DOI":"10.1016\/j.berh.2021.101693","volume":"35","author":"BCK Ng","year":"2021","unstructured":"Ng BCK, Jadon DR. Unmet needs in psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101693.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"3788_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10067-023-06745-y","volume":"43","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Gottlieb AB, Ogdie A, McInnes IB, Chakravarty SD, Rampakakis E, et al. Earlier clinical response predicts low rates of radiographic progression in biologic-na\u00efve patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2024;43(1):241\u20139.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3788_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/PTT.S328460","volume":"1","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M. Towards Personalized Medicine in Psoriasis: Current Progress. Psoriasis Targets Ther. 2022;1(12):231\u201350.","journal-title":"Psoriasis Targets Ther"},{"issue":"10","key":"3788_CR11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3390\/biomedicines10102387","volume":"10","author":"R Gurke","year":"2022","unstructured":"Gurke R, Bendes A, Bowes J, Koehm M, Twyman RM, Barton A, et al. Omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis. Biomedicines. 2022;10(10):2387.","journal-title":"Biomedicines"},{"issue":"11","key":"3788_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41584-020-00507-9","volume":"16","author":"DR Jadon","year":"2020","unstructured":"Jadon DR, Stober C, Pennington SR, FitzGerald O. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol. 2020;16(11):609\u201327.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"3788_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/03008207.2025.2541291","volume":"66","author":"PMJ Welsing","year":"2025","unstructured":"Welsing PMJ, el Bouhaddani S, Zhu L, Nijhof NC, Mastbergen SC, Wen C, et al. Omics-driven insights into the molecular pathways driving osteoarthritis pathogenesis. Connect Tissue Res. 2025;66(5):323\u201330.","journal-title":"Connect Tissue Res"},{"issue":"1","key":"3788_CR14","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2665-9913(19)30008-6","volume":"1","author":"H Al-Mossawi","year":"2019","unstructured":"Al-Mossawi H, Taams LS, Goodyear CS, Kirkham BW, McInnes IB, Siebert S, et al. Precision medicine in psoriatic arthritis: how should we select targeted therapies? Lancet Rheumatol. 2019;1(1):e66-73.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"3788_CR15","doi-asserted-by":"publisher","first-page":"102949","DOI":"10.1016\/j.autrev.2021.102949","volume":"20","author":"A Grivas","year":"2021","unstructured":"Grivas A, Fragoulis G, Garantziotis P, Banos A, Nikiphorou E, Boumpas D. Unraveling the complexities of psoriatic arthritis by the use of -Omics and their relevance for clinical care. Autoimmun Rev. 2021;20(11):102949.","journal-title":"Autoimmun Rev"},{"key":"3788_CR16","doi-asserted-by":"publisher","first-page":"1759720X2110140","DOI":"10.1177\/1759720X211014010","volume":"13","author":"C Magee","year":"2021","unstructured":"Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"Suppl 2","key":"3788_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/annrheumdis-2019-eular.479","volume":"78","author":"S Siebert","year":"2019","unstructured":"Siebert S, Loza MJ, Song Q, Mcinnes I, Sweet K. Thu0052 Ustekinumab and Guselkumab Treatment Results in Differences in Serum Il17a, Il17f and Crp Levels in Psoriatic Arthritis Patients: A Comparison from Ustekinumab Ph3 and Guselkumab Ph2 Programs. Ann Rheum Dis. 2019;78(Suppl 2):293\u2013293.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3788_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s10067-010-1528-x","volume":"29","author":"SJ Pedersen","year":"2010","unstructured":"Pedersen SJ, Hetland ML, S\u00f8rensen IJ, \u00d8stergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNF\u03b1 inhibitors. Clin Rheumatol. 2010;29(11):1301\u20139.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"3788_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3899\/jrheum.121162","volume":"40","author":"V Chandran","year":"2013","unstructured":"Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, et al. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40(6):866\u201371.","journal-title":"J Rheumatol"},{"issue":"1","key":"3788_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","volume":"27","author":"S Muramatsu","year":"2017","unstructured":"Muramatsu S, Kubo R, Nishida E, Morita A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol. 2017;27(1):137\u201341.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"3788_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","volume":"72","author":"CL Wagner","year":"2013","unstructured":"Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72(1):83\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3788_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/BOR.0000000000001086","volume":"37","author":"D Ganatra","year":"2025","unstructured":"Ganatra D, Chandran V. Biomarker discovery in psoriatic disease. Curr Opin Rheumatol. 2025;37(4):225.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"3788_CR23","doi-asserted-by":"publisher","first-page":"e064338","DOI":"10.1136\/bmjopen-2022-064338","volume":"12","author":"NJ Kleinrensink","year":"2022","unstructured":"Kleinrensink NJ, Perton FT, Pouw JN, Vincken NLA, Hartgring SAY, Jansen MP, et al. TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open. 2022;12(10):e064338.","journal-title":"BMJ Open"},{"issue":"1","key":"3788_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-025-03660-2","volume":"27","author":"FT Perton","year":"2025","unstructured":"Perton FT, Bentvelzen MLM, Fadaei S, Pouw JN, Spierings J, Vonkeman HE, et al. The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis. Arthritis Res Ther. 2025;27(1):197.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"3788_CR25","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3788_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3788_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"4","key":"3788_CR28","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLoS One. 2014;9(4):e95192.","journal-title":"PLoS One"},{"issue":"1","key":"3788_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P. MissForest\u2014non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112\u20138.","journal-title":"Bioinformatics"},{"key":"3788_CR30","unstructured":"Chen T, He T, Benesty M, Khotilovich V, Tang Y, Cho H, et al. xgboost: Extreme Gradient Boosting. 2014. p. 1.7.11.1. Available from: https:\/\/CRAN.R-project.org\/package=xgboost. Cited 2025 Jun 11."},{"issue":"1","key":"3788_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1471-2105-12-253","volume":"12","author":"KA L\u00ea Cao","year":"2011","unstructured":"L\u00ea Cao KA, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics. 2011;12(1):253.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"3788_CR32","doi-asserted-by":"publisher","first-page":"e1011809","DOI":"10.1371\/journal.pcbi.1011809","volume":"20","author":"S el Bouhaddani","year":"2024","unstructured":"el Bouhaddani S, H\u00f6llerhage M, Uh HW, Moebius C, Bickle M, H\u00f6glinger G, et al. Statistical integration of multi-omics and drug screening data from cell lines. PLOS Comput Biol. 2024;20(1):e1011809.","journal-title":"PLOS Comput Biol"},{"issue":"1","key":"3788_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12859-018-2371-3","volume":"19","author":"S el Bouhaddani","year":"2018","unstructured":"el Bouhaddani S, Uh HW, Jongbloed G, Hayward C, Klari\u0107 L, Kie\u0142basa SM, et al. Integrating omics datasets with the OmicsPLS package. BMC Bioinformatics. 2018;19(1):371.","journal-title":"BMC Bioinformatics"},{"issue":"26","key":"3788_CR34","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1002\/sim.9154","volume":"40","author":"J Hoogland","year":"2021","unstructured":"Hoogland J, IntHout J, Belias M, Rovers MM, Riley RD, E. Harrell JF, et al. A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint. Stat Med. 2021;40(26):5961\u201381.","journal-title":"Stat Med"},{"issue":"D1","key":"3788_CR35","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u201346.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3788_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","volume":"27","author":"S Muramatsu","year":"2017","unstructured":"Muramatsu S, Kubo R, Nishida E, Morita A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol. 2017;27(1):137\u201341.","journal-title":"Mod Rheumatol"},{"key":"3788_CR37","doi-asserted-by":"crossref","unstructured":"Sahoo SR, Das K, Panda B, Pandey M, Acharya M, Meher P, et al. Serum Interleukin (IL)-6, Lipid Profile, and Association With Disease Severity in Patients With Psoriasis: A Cross-Sectional Study. Cureus. 2024;16(9). Available from: https:\/\/cureus.com\/articles\/256984-serum-interleukin-il-6-lipid-profile-and-association-with-disease-severity-in-patients-with-psoriasis-a-cross-sectional-study. Cited 2025 Sep 8.","DOI":"10.7759\/cureus.69599"},{"issue":"1","key":"3788_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10517-022-05497-0","volume":"173","author":"VV Sobolev","year":"2022","unstructured":"Sobolev VV, Denisova EV, Chebysheva SN, Geppe NA, Korsunskaya IM. IL-6 Gene Expression as a Marker of Pathological State in Psoriasis and Psoriatic Arthritis. Bull Exp Biol Med. 2022;173(1):77\u201380.","journal-title":"Bull Exp Biol Med"},{"issue":"19","key":"3788_CR39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cca.2012.05.007","volume":"413","author":"T Elango","year":"2012","unstructured":"Elango T, Dayalan H, Subramanian S, Gnanaraj P, Malligarjunan H. Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. Clin Chim Acta. 2012;413(19):1652\u20136.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"3788_CR40","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2021-220280","volume":"80","author":"N Yager","year":"2021","unstructured":"Yager N, Cole S, Lara AL, Maroof A, Penkava F, Knight JC, et al. Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid. Ann Rheum Dis. 2021;80(12):1559\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3788_CR41","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3899\/jrheum.081156","volume":"36","author":"L Masi","year":"2009","unstructured":"Masi L, Ricci L, Zulian F, Monte FD, Simonini G, Capannini S, et al. Serum Osteopontin as a Predictive Marker of Responsiveness to Methotrexate in Juvenile Idiopathic Arthritis. J Rheumatol. 2009;36(10):2308\u201313.","journal-title":"J Rheumatol"},{"issue":"12","key":"3788_CR42","doi-asserted-by":"publisher","first-page":"e0145468","DOI":"10.1371\/journal.pone.0145468","volume":"10","author":"K Izumi","year":"2015","unstructured":"Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T. Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-na\u00efve patients with rheumatoid arthritis: a single-center prospective study at 1 year (the Keio First-Bio Cohort Study). PLoS One. 2015;10(12):e0145468.","journal-title":"PLoS One"},{"issue":"3","key":"3788_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1600-0625.2006.00406.x","volume":"15","author":"T Hohwy","year":"2006","unstructured":"Hohwy T, Otkjaer K, Madsen J, S\u00f8erensen G, Nielsen O, Vestergaard C, et al. Surfactant protein D in atopic dermatitis and psoriasis. Exp Dermatol. 2006;15(3):168\u201374.","journal-title":"Exp Dermatol"},{"issue":"7","key":"3788_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00403-008-0846-1","volume":"300","author":"A Akman","year":"2008","unstructured":"Akman A, Kankavi O, Ciftcioglu MA, Alpsoy E. Surfactant proteins in inflammatory skin diseases: controlled study. Arch Dermatol Res. 2008;300(7):353\u20136.","journal-title":"Arch Dermatol Res"},{"issue":"13","key":"3788_CR45","doi-asserted-by":"publisher","first-page":"e120682","DOI":"10.1172\/jci.insight.120682","volume":"3","author":"AA Merleev","year":"2018","unstructured":"Merleev AA, Marusina AI, Ma C, Elder JT, Tsoi LC, Raychaudhuri SP, et al. Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17A. JCI Insight. 2018;3(13):e120682.","journal-title":"JCI Insight"},{"key":"3788_CR46","doi-asserted-by":"crossref","unstructured":"Dolcino M, Pelosi A, Fiore PF, Patuzzo G, Tinazzi E, Lunardi C, et al. Long Non-Coding RNAs Play a Role in the Pathogenesis of Psoriatic Arthritis by Regulating MicroRNAs and Genes Involved in Inflammation and Metabolic Syndrome. Front Immunol. 2018;9. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2018.01533\/full. Cited 2025 Sep 8.","DOI":"10.3389\/fimmu.2018.01533"},{"issue":"1","key":"3788_CR47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/rheumatology\/kead195","volume":"63","author":"H Johnsson","year":"2024","unstructured":"Johnsson H, Cole J, McInnes IB, Graham G, Siebert S. Differences in transcriptional changes in psoriasis and psoriatic arthritis skin with immunoglobulin gene enrichment in psoriatic arthritis. Rheumatology. 2024;63(1):218\u201325.","journal-title":"Rheumatology"},{"issue":"1","key":"3788_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41368-021-00146-0","volume":"13","author":"X Li","year":"2021","unstructured":"Li X, Wang CY. From bulk, single-cell to spatial RNA sequencing. Int J Oral Sci. 2021;13(1):36.","journal-title":"Int J Oral Sci"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03788-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03788-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03788-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:04:42Z","timestamp":1775750682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03788-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3788"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03788-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. The study was carried out in compliance with the Declaration of Helsinki and was approved by the Medical Research Ethics Committee in Utrecht, Netherlands (MREC reference number: NL63439.041.17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.E.V. is paid consultant for (pharmaceutical) companies Abbvie, Novartis, Pfizer, UCB, Johnson and Johnson, Alphasigma, he received speaker fees from AstraZeneca, Lilly, Pfizer, and he received research grants from (pharmaceutical) companies: Galapagos and Boehringer Ingelheim. S.C.M. is supported by ReumaNederland LLP-9. J.S. received research grants from ReumaNederland, Vifor, Vasculitis Stichting, Zeldzame Ziektenfonds and Miltenyi Biotec, and she received speaker fees from Boehringer Ingelheim, Janssen and Novartis. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}